GSA Capital Partners LLP Has $56,000 Stock Position in Adicet Bio, Inc. (NASDAQ:ACET)

GSA Capital Partners LLP lifted its stake in shares of Adicet Bio, Inc. (NASDAQ:ACET) by 161.3% during the third quarter, Holdings Channel.com reports. The firm owned 39,208 shares of the company’s stock after acquiring an additional 24,203 shares during the period. GSA Capital Partners LLP’s holdings in Adicet Bio were worth $56,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. RA Capital Management L.P. bought a new position in Adicet Bio in the first quarter worth approximately $17,721,000. Vanguard Group Inc. raised its position in shares of Adicet Bio by 85.5% during the first quarter. Vanguard Group Inc. now owns 3,126,578 shares of the company’s stock worth $7,347,000 after purchasing an additional 1,441,503 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Adicet Bio by 44.2% in the 2nd quarter. Renaissance Technologies LLC now owns 1,512,600 shares of the company’s stock worth $1,830,000 after purchasing an additional 463,600 shares in the last quarter. Acadian Asset Management LLC grew its position in Adicet Bio by 205.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,085,093 shares of the company’s stock valued at $1,312,000 after purchasing an additional 729,750 shares during the period. Finally, Stonepine Capital Management LLC increased its stake in Adicet Bio by 330.6% during the 2nd quarter. Stonepine Capital Management LLC now owns 609,446 shares of the company’s stock valued at $737,000 after purchasing an additional 467,898 shares in the last quarter. 83.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ACET. Canaccord Genuity Group dropped their price objective on shares of Adicet Bio from $19.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, September 11th. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Adicet Bio in a research report on Thursday, November 7th. StockNews.com downgraded Adicet Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. HC Wainwright reissued a “neutral” rating on shares of Adicet Bio in a research note on Monday, November 18th. Finally, Guggenheim initiated coverage on Adicet Bio in a research report on Monday, September 30th. They set a “buy” rating and a $7.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Adicet Bio currently has an average rating of “Hold” and an average price target of $7.50.

Adicet Bio Price Performance

ACET opened at $0.90 on Tuesday. Adicet Bio, Inc. has a fifty-two week low of $0.89 and a fifty-two week high of $3.77. The firm has a market capitalization of $74.49 million, a P/E ratio of -0.53 and a beta of 1.81. The company’s 50-day moving average is $1.32 and its 200 day moving average is $1.38.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, meeting the consensus estimate of ($0.34). On average, equities research analysts expect that Adicet Bio, Inc. will post -1.39 earnings per share for the current year.

Adicet Bio Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.